GROUP: MAD ED FILE MAD TE IF APPROXIMATE ATTY. DOCKET NO.: 10447-022 Form PTO-1449 DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 2-32) APPLICANTS: Curtis Braun et al. INFORMATION DISCLOSURE STATEMENT BY APPLICANT FILING DATE: October 4, 2000 (Use several sheets if necessary) U.S. PATENT DOCUMENTS SUB-DOCUMENT \*EXA-CLASS CLASS MINER NUMBER DATE NAME INITIAL Lifson et al. 1989-09-25 4,869,903 Piatak Jr. et al. 1992-03-31 5,101,025 1992-07-07 Piatak Jr. et al. 5,128,460 FOREIGN PATENT DOCUMENTS SUB-TRANSLATION DOCUMENT CLASS DATE COUNTRY YES NUMBER **CLASS** 1992-01-15 Europe EP 145,111 1985-06-19 Europe EP 466,222 1989-06-01 **PCT** WO89/04839 **PCT** 1994-08-18 WO94/18332 1997-11-06 PCT WO97/41233 **PCT** 1998-11-05 WO98/49311 OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) Abad-Zapatero, C. et al., Protein Sci. 5:640-652 (1996) 2. Allured, V.S. et al., Proc. Natl. Acad. Sci. USA 83:1320-1324 (1986) Bever Jr., C.T., Panitch, H.S., and Johnson, K.P. (1994) Neurology 44(4), 745-8. 4. Blackman, M.J. et al. (Mol. Biochem. Parasitol. 62:103-114 (1995) 1993 5. Blaha, I. et al., FEBS Lett. 309:389-393 (1992) EXAMINER: Initial if citation considered, whether or not citation is in accordance with MPEP 609; draw line through citation if not

in conformance and not considered. Include copy of this form with next communication to applicant.

MARK NOVARRO



	<b>∠</b> 0	1000			
Form PTO-1449	0.	DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.: 10447-022	SERIAL NO.: 10/089,058	
(REV. 2-32) PATENT AND TRADEMARK OFFICE			APPLICANTS: Curtis Braun et al.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: October 4, 2000	GROUP:	
(Use several sheets if necessary) FILING DATE: October 4, 2000 GROUP:					
		Г	(including Author, Title, Date, Pertinent Pages	, Etc.)	
$\sim$	6.	PICLOSURE STATEMENT Veral sheets if necessary)  FILING DATE: October 4, 2000  GROUP:  OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)  Blum, J.S. et al., J. Biol. Chem. 266: 22091-22095 (1991)  Bonifacino, J.S., Nature 384: 405-406 (1996)  Carvalho, K. et al., Biochem. Biophys. Res. Comm. 191:172-179 (1993)  Chirgwin et al., Biochemistry 18, 5294-5299 (1979)  Cohen, P., Graves, H.C., Peehl, D.M., Kamarei, M., Giudice, L.C., and Rosenfeld, R.G.			
$\sim$	7.	Bonifacino, J.S., Nature 384		CENT	
~	8.	Carvalho, K. et al., Biochen	chem. Biophys. Res. Comm. 191:172-179 (1993)		
~	9.	Chirgwin et al., Biochemisti	try 18, 5294-5299 (1979)		
$\sim$	10.	Cohen, P., Graves, H.C., Peehl, D.M., Kamarei, M., Giudice, L.C., and Rosenfeld, R.G. (1992) Journal of Clinal Endocrinology and Metabolism 75(4), 1046-53.			
$\sim$	11.	Collier, R.J. & Kandel, J., J. Biol. Chem. 246:1496-1503 (1971)			
$\sim$	12.	Collier, R.J. et al., J. Biol. Chem. 257:5283-5285 (1982)			
$\sim$	13.	Columblatti, M. et al., J. Biol. Chem. 261:3030-3035 (1986)			
~	14.	Conover, C.A. and De Leon, D.D., J. Biol. Chem. 269(10), 7076-80 (1994)			
~	15.				
N	16.				
~	17.				
~	18.				
~	19.				
~	20.				
~	21.	Endo, Y. & Tsurugi, K. J., Biol. Chem. 262:8128 (1987)			
0.0	22.	Fiani, M.L. et al., Arch. Biochem. Biophys. 307: 225-230 (1993)			
~	23.	Funmatsu et al., Jap. J. Med. Sci. Biol. 23:264-267 (1970)			
~	24.	Fusek, M. et al. (FEBS Lett. 327:108-112 (1993)			
~	25.	Garred, O. et al. (J. Biol. Chem. 270:10817-10821 (1995)			
~	26.	Gluzman, Y. (1975) Cell, 23, 175 - 182)			
~	27.	Goldberg, D.E. et al. (J. Exp. Med. 173:961-969 (1991)			
~	28.	Gray, G.L. et al., Proc. Natl. Acad. Sci. USA 81:2645-2649 (1984)			
~	29.	Greenfield, L. et al., Proc. Natl. Acad. Sci. USA 80:6853-6857 (1983)			
	30.				
~	31.				
			of citation is in accordance with MPEP 609; draw li		
			de copy of this form with next communication to a		

MARK NAVARRO

	2					
Form PTO-1449		TENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 10447-22	SERIAL NO.: 10/089,058		
(REV. 2-32) PATENT AND TRADEMARK OFFICE			APPLICANTS: Curtis Braun et al.			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			FILING DATE: October 4, 2000	GROUP:		
		OTHER DOCUMENTS	(including Author, Title, Date, Pertinent P	ages, Etc.)		
$\sim$	32.	Hirowatari, Y. et al., Arch.	Virol. 133:349-356 (1993)	7		
~	33.	Hirowatari, Y. et al., Anal.	Biochem. 225:113-120 (1995)	Ages, Etc.)  Ages, Etc.)  Compared to the comp		
~	34.	Holmberg, K. and Myer, R.,	Scand. J. Infect. Dis. 18:179-192 (1986	) CHO TO		
N	35.	Honn, K.V. et al. (Biochem. Pharmacol. 34:235-241 (1985)				
^	36.	Jewell, D.A. et al., Biochemistry 31:7862-7869 (1992)				
~	37.	Krane, S.M., Ann: N.Y. Acad. Sci. 732:1-10 (1994)				
~	38.	Lamb and Lord, Eur. J. Bioch	nem. 14:265-270 (1985)			
~	39.	Leppla, S.H. et al. (Bacterial Protein Toxins zbl.bakt.suppl. 24:431-442 (1994)				
~	40.	Liu F. & Roizman, B. (J. Virol. 65:5149-5156 (1991)				
~	41.	Long, A.C. et al., FEBS Lett. 258:75-78 (1989)				
~	42.	Lord, J.M., Eur. J. Biochem. 146:411-416 (1985)				
$\sim$	43.	Lord, J.M., Eur. J. Biochem. 146:403-409 (1985)				
~	44.	Lord, J.M. et al., FASAB Journal 8:201-208 (1994)				
$\sim$	<b>4</b> 5.	Mackay, A.R. et al. Lab. Invest. 70:800-806 (1994)				
~~	46.	May, M.J. et al. Embo. Journal, 8:301-308 at 302-303 (1989)				
$\sim$	47.	McKerrow, J.H. et al., J. Biol. Chem. 260:3703-3707 (1985)				
$\sim$	48.	McPherson, R.A. et al. (Mol. Biochem. Parasitol. 62:233-242 (1993)				
$\sim$	49.	Mikkelsen, T. et al. J. Neurosurge, 83:285-290 (1995)				
~	50.	Moore, D.H. et al. Gynecol. Oncol. 65:78-82 (1997)				
~	51.	Muller, H.L., Oh, Y., Gargosky, S.E., Lehrnbecher, T., Hintz, R.L., and Rosenfeld, R.G. (1993) Journal of Clinical Endocrinology and Metabolism 77(5), 1113-9.				
~	52.	Nakano et al. (1995) J. of Neurosurgery 83(2), 298-307				
~	53.	Nwagwu, M. et al. (Exp. Parasitol. 75:399-414 (1992)				
• EXAMINER:			ot citation is in accordance with MPEP 609; dra de copy of this form with next communication			

MARE NAVARDO



	<u> </u>	TRADE			
Form PTO-144		S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.: 10447-022	SERIAL NO.: 10/089,058	
(REV. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT			APPLICANTS: Curtis Braun et al.		
BY APPLICANT  (Use several sheets if necessary)			FILING DATE: October 4, 2000	GROUP:	
<del> </del>		OTHER DOCUMENTS	(including Author, Title, Date, Pertinent Page	es, Etc.)	
~	54.	O'Dea, K.P. et al., Mol. Biochem. Parasitol. 72:111-119 (1995)			
~	55.	Ogata, M. et al., J. Biol. Che	(including Author, Title, Date, Pertinent Pages, Etc.)  Chem. Parasitol. 72:111-119 (1995)  Chem. 267:25396-25401 (1992)		
~	56.	Olsnes, S. & Phil, A. in Molecular action of toxins and viruses (eds. Cohen, P. & vanHeyningen, S.) 51-105 Elsevier Biomedical Press, Amsterdam, 1982)			
~	57.	Olson et al., AIDS Res. and Human Retroviruses 7:1025-1030 (1991)			
~	58.	Panchal, R.G. et al., Nature Biotechnology 14:852-857 (1996)			
$\sim$	59.	Pastan et al., Annals New York Academy of Sciences 758:345-353 (1995)			
	60.	Pastan, I. et al., Annu. Rev. Biochem. 61:331-354 (1992)			
~	61.	Peng, K-W, et al. Human Gene Therapy, 8:729-738 (1997)			
~	62.	Pettit, S.C. et al., J. Biol. Chem. 266:14539-14547 (1991)			
$\sim$	63.	Ray, T.L. and Payne, C.D. (Infect. Immunol. 58:508-514 (1990)			
~	64.	Remold, H.H. et al. (Biochim. Biophys. Acta 167:399-406 (1968)			
~	65.	Richardson, P.T. et al., FEBS Lett. 255:15-20 (1989)			
$\sim$	66.	Rosenthal, P.J. et al. (J. Clin. Invest. 91:1052-1056 (1993)			
n	67.	Ruchel, R. et al, Zentralbl. Bakteriol. Mikrobiol Hyg. I Abt. Orig. A. 255:537-548 (1983)			
$\sim$	68.	Rutenber, E. et al. Proteins 10:240-250 (1991)			
~	69.	Sandvig, K. et al., Biochem. Soc. Trans. 21:707-711 (1993)			
$\sim$	70.	Sandvig, K. & van Deurs, B., FEBS Lett. 346: 99-102 (1994)			
N	71.	Scarborough, P.E. et al., Protein Sci. 2:264-276 (1993)			
M	72.	Schreiber, B, et al., Diagn. Microbiol. Infect. Dis. 3:1-5 (1985)			
~	73.	Schwartz, M.K., Clin. Chim. Acta 237:67-78 (1995)			
~	74.	Shi, Y.E. et al., Cancer Res. 53:1409-1415 (1993)			
N	75.	Simmons et al., Biol. Chem.	261:7912 (1986)		
~	76.	Sloane, B.F. et al. (Proc. Nat	l. Acad. Sci. USA 83:2483-2487 (1986)		
EXAMINER:	Initial in cor	if citation considered, whether or no nformance and not considered. Inclu	t citation is in accordance with MPEP 609; draw li de copy of this form with next communication to a	ine through citation if not applicant.	

MARK

NAVARED

Form PTO-14	49 ' U.	DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.: 10447-022	SERIAL NO.: 10/089,058				
(REV. 2-32) PATENT AND TRADEMARK OFFICE			APPLICANTS: Curtis Braun et al.					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT								
(Use several sheets if necessary)			FILING DATE: October 4, 2000	GROUP:				
	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)							
~	77.	Spiess, E. et al., J. Histocher	m. Cytochem. 42:917-929 (1994)	The second second				
~	78.	Spooner et al., Mol. Immunol. 31:117-125, (1994)						
1	79.	Thompson, E.W. et al., Breast Cancer Res. Treatment 31:357-370 (1994)						
~	80.	Spooner et al., Mol. Immunol. 31:117-125, (1994)  Thompson, E.W. et al., Breast Cancer Res. Treatment 31:357-370 (1994)  Vasil, M.L. et al., Infect. Immunol. 16:353-361 (1977)						
~	81.	Vitetta et al., Science 238:1098-1104(1987)						
N	82.	Vitetta & Thorpe, Seminars in Cell Biology 2:47-58 (1991)						
~	83.	Vitetta et al., Immunology Today 14:252-259 (1993)						
~	84.	Weidner, J.R. et al. (Arch. Biochem. Biophys. 286:402-408 (1991)						
~	85.	Welch, A.R. et al. (Arch. Biochem. Biophys. 324:59-64 (1995)						
~	86.	Welch, A.R. (Proc. Natl. Acad. Sci. USA 88:10792-10796 (1991)						
~ ~ ~ ~	87.	Wellner, R.B. et al. J. Toxicol. Toxin Reviews, 14(4), 483-522 (1995)						
~	88.	Westby et al., Bioconjugate Chem. 3:377-382 (1992)						
	89.	Weston et al., Mol. Biol. 244:410-422 (1994)						
~	90.	Wiertz, E.J. et al., Nature 384: 432-438 (1996)						
~	91.	Woessner, J.F., Ann. N.Y. Acad. Sci. 732:11-21 (1994)						
~	92.	Young, T.N. et al. Gynecol. (	Oncol. 62:89-99 (1996)					
	93.		,					
	94.							
	95.							
	96.		·					
	97.		·					
	98.							
	99.							
	100.							
	101.	•						
	102.							
* EXAMINER: Initial if citation considered, whether or not citation is in accordance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

MARK NAVAROW